Medication Management Note Template: Example & Guide for Prescribers

What Is a Medication Management Note?

A medication management note — often called a med management note, medication check note, or psychiatric follow-up note — documents an appointment whose purpose is evaluating and adjusting psychiatric medication. This guide includes a blank template you can download plus two fully written examples: a standard antidepressant follow-up and an antipsychotic-monitoring visit with AIMS documentation. The note records the patient's response to the current regimen, adherence, side effects, safety monitoring, a focused mental status examination, a risk assessment, and the prescriber's reasoning for continuing or changing treatment.

These notes are written by prescribers: psychiatrists, psychiatric-mental health nurse practitioners (PMHNPs), physician assistants/associates working in behavioral health, and some primary care clinicians who manage psychotropic medication. PMHNP prescriptive authority varies by state — the AANP classifies states as full, reduced, or restricted practice, and over half of U.S. states now grant full practice authority — so check the AANP state practice environment map for your jurisdiction rather than assuming a single national rule.

If you are a therapist rather than a prescriber, you will not write this note, but you will read them, coordinate around them, and be asked to exchange information with the clinicians who write them. Understanding the structure helps you interpret a prescriber's reasoning, know what collateral information is useful to send, and document your own collateral contacts with the prescribing clinician.

The visit itself is typically shorter than a therapy session — often 15 to 30 minutes — and the note is correspondingly focused. It is not a condensed therapy note; it is a different document with a different job: creating a clear pharmacological decision trail.

Medication Management Note vs. Therapy Note

The cleanest way to understand the difference is through the HIPAA Privacy Rule itself. Under 45 CFR § 164.501, "psychotherapy notes" are notes by a mental health professional documenting or analyzing the contents of conversation during a counseling session, kept separate from the rest of the medical record. The definition then explicitly excludes "medication prescription and monitoring," along with session start and stop times, modalities and frequencies of treatment, results of clinical tests, and any summary of diagnosis, functional status, treatment plan, symptoms, prognosis, and progress to date.

That exclusion settles the question: a medication management note is a progress note in the general medical record. It never qualifies for the heightened psychotherapy-notes protections, no matter where it is stored. It is the record that other treating providers, covering clinicians, and payers may legitimately access. For the full breakdown of the two record types, see psychotherapy notes vs. progress notes.

Beyond the legal status, the two documents differ on every practical axis:

• Purpose. A therapy note documents interventions delivered and the client's response within a psychotherapeutic frame. A medication management note documents a pharmacological decision trail — what is being prescribed, how the patient is responding, and why each change was made.
• Author. Any licensed therapist writes therapy progress notes. Medication management notes are written by prescribers acting within their scope.
• Structure. A therapy note is organized around interventions and response (SOAP, DAP, BIRP). A medication management note is organized around the medication itself: systematic adherence and side-effect review, monitoring data, and a plan with dose-level specificity.
• Content boundaries. Session process, transference material, and detailed exploration of conversation content belong in therapy documentation. The medication note records symptoms, response, and safety — not the narrative of the conversation.
• Length and cadence. Therapy notes recur weekly with the session; medication notes typically recur at 2-week to 3-month intervals depending on stability, and are usually shorter.

Key Components

Interval History

Open with the patient's status since the last visit: symptom trajectory in each target domain, sleep, appetite, energy, concentration, substance use, and significant life events that bear on treatment. Anchor the interval history to rating scales where your clinic uses them — a PHQ-9 or GAD-7 trend line communicates response faster than a paragraph of prose. Note the source of information if anyone besides the patient contributed (family member present, therapist report, pharmacy records).

Medication Review

List the current regimen with drug, dose, and schedule — every visit, even when nothing changed. Then document two things systematically:

Adherence. Not just "adherent" — ask about missed doses and why. Cost, side effects, ambivalence about taking medication, and simple forgetting each lead to different plans.

Side effects. Query systematically rather than waiting for spontaneous report: sexual side effects, GI symptoms, weight change, sedation, activation, and anything class-specific. For patients on medications requiring laboratory monitoring — lithium levels, valproate levels and hepatic panels, clozapine absolute neutrophil counts — record the most recent results and when the next draw is due. For patients on second-generation antipsychotics, document metabolic monitoring (weight/BMI, glucose or A1c, lipids) consistent with the APA schizophrenia guideline's recommendations.

Movement Screening and the AIMS (Antipsychotics)

For any patient on an antipsychotic, the APA Practice Guideline for the Treatment of Patients with Schizophrenia (2020) recommends clinical assessment of akathisia, dystonia, parkinsonism, and other abnormal involuntary movements — including tardive dyskinesia — at each visit, plus assessment with a structured instrument such as the AIMS or DISCUS at minimum every 6 months for patients at high risk of tardive dyskinesia and at least every 12 months for other patients, and whenever new or worsening movements appear.

The Abnormal Involuntary Movement Scale (AIMS) is a 12-item examination covering orofacial, extremity, and truncal movements plus global severity, incapacitation, and patient awareness, with movement items scored 0 (none) to 4 (severe). It was developed by NIMH and is in the public domain, so you may embed the full scale in your own note templates. As a summary reference point, the widely used Schooler-Kane research criteria consider tardive dyskinesia probable when there is at least mild movement in two or more body regions or moderate movement in one region, in a patient with at least three months of cumulative antipsychotic exposure — but treat that as context for interpreting scores, and document your clinical judgment, not just a number.

In the note, record the date the structured exam was last completed, today's findings (or "AIMS completed today, score summarized below"), and the plan if anything changed.

Brief Mental Status Examination

Document a focused MSE: appearance, behavior, speech, mood, affect, thought process, thought content, cognition where indicated, and insight/judgment. This is deliberately briefer than an intake MSE — one line per domain is typical, expanding wherever findings are abnormal or changed. See the mental status exam guide for full descriptive vocabulary; a medication note borrows the same terms at lower resolution.

Risk Assessment

Every visit, without exception: suicidal ideation, homicidal ideation, access to means where relevant, and protective factors. Several psychotropics carry their own risk-relevant considerations — early treatment activation, quantity of medication supplied to a patient with elevated risk — so the risk statement and the prescribing plan should visibly connect. When risk is elevated, document the fuller assessment described in the risk assessment guide and the specific actions taken.

Assessment and Plan

State the diagnosis and its current status (improving, stable, worsening, in remission), then give the medication plan with rationale. "Continue sertraline 100 mg" is a decision; "Continue sertraline 100 mg — partial response at week 6 with PHQ-9 improved from 18 to 11, tolerating well; will reassess for dose increase in 4 weeks if residual symptoms persist" is a decision trail. Every start, stop, dose change, and cross-taper needs a documented why. Close with labs ordered, the informed-consent or patient-education discussion (risks, benefits, alternatives discussed for any new medication), coordination of care, and the follow-up interval.

Medication Management Note Example (Standard Follow-Up)

The two filled-in examples below — a routine antidepressant follow-up here, and an antipsychotic-monitoring visit in the next section — describe fictional patients. All names, initials, dates, and clinical details are invented.

Example with Antipsychotic Monitoring (AIMS Documented)

Try this template in My Clinical WriterDownload Medication Management Note Template (.docx)Share

How to Write It Step by Step

Step 1: Review before the visit, and count that time. Scan the last note, interval labs, rating scales, and any therapist or pharmacy communication. Under the E/M framework in place since 2021, total time on the date of service includes this non-face-to-face work — reviewing records and documenting — not just the face-to-face encounter.

Step 2: Open with the interval history, anchored to measures. Ask about each target symptom domain, sleep, appetite, energy, substances, and life events. Record the current rating-scale score next to prior scores so the trajectory is visible in one line.

Step 3: Reconcile the medication list every visit. Restate the full regimen with doses — including non-psychiatric medications when they interact — and ask specifically about missed doses and the reason for them.

Step 4: Query side effects systematically. Walk through the class-relevant list rather than asking "any side effects?" Patients underreport sexual side effects, weight concerns, and cognitive dulling unless asked directly. Record pertinent negatives; an unasked question and a negative finding look identical in a silent chart.

Step 5: Complete the monitoring appropriate to the regimen. Levels and labs for lithium, valproate, and clozapine; metabolic parameters for second-generation antipsychotics; clinical movement check every visit for any antipsychotic, with a structured AIMS at guideline intervals. Document what was done, the result, and when the next one is due.

Step 6: Record a brief MSE and a risk statement. One line per MSE domain, expanded where abnormal. Risk assessment every visit — including the connection between risk level and your prescribing decisions.

Step 7: Write the assessment and plan as a decision trail. For every continue, start, stop, or change: the decision, the clinical reasoning, and the data supporting it. Document the informed-consent discussion for anything new — risks, benefits, and alternatives reviewed.

Step 8: Close with coordination and follow-up. Note communication with the treating therapist or primary care clinician, labs ordered, patient education provided, and a specific follow-up interval with instructions for seeking care sooner.

Documentation Quality Tips

Support your medical decision making — or your time. Since the 2021 AMA/CMS revisions, office visit levels are selected by either medical decision making or total time on the date of service; history and exam no longer drive code selection, though a medically appropriate history and examination must still be performed and documented. For a medication management note, that means the note should clearly reflect the diagnoses addressed, the data reviewed (labs, scales, collateral), and the risk inherent in medication management decisions — or the total time spent. Keep it at that level of generality in your own thinking too: do not build the note around a target code. Coding questions belong with your coder or payer, not your template.

Give every change a rationale. Auditors, covering prescribers, and future-you all need the same thing: why. A regimen history without reasons is a list; with reasons it is a treatment record.

Document the conversation, not just the prescription. Informed-consent discussions, warnings reviewed, patient preferences honored (as with the patient above declining a change for a tolerable side effect) — these show shared decision making and are among the most protective lines in the note.

Resist copy-forward drift. Carrying yesterday's interval history into today's note is the fastest way to make the whole chart untrustworthy. Templates should pre-fill structure, never findings. If you must reference a prior note, cite it ("MSE unchanged from 03/05/2026 except...") rather than cloning it. And if something must be added after signing, use a proper late entry or addendum.

Mind the telehealth details. Medication follow-ups are frequently virtual; document modality, patient location, and consent as you would for any telehealth session note, plus any prescribing constraints that apply to remote visits in your jurisdiction.

Common Mistakes

1. Treating it as a mini therapy note. Session narrative and process content are the wrong skeleton. A medication management note that spends three paragraphs on the conversation and one line on "continue meds" has inverted its priorities — the medication reasoning is the point.

2. Documenting adherence and side effects only when problematic. "Adherent, no side effects reported" after a systematic query is clinically meaningful; silence is not. Pertinent negatives are what distinguish an assessed patient from an unassessed one.

3. Letting movement screening lapse. The clinical check belongs in every antipsychotic visit and the structured AIMS on a tracked schedule. A chart with years of antipsychotic prescriptions and no documented movement assessment is a serious gap — clinically, not just administratively.

4. Changing doses without documented reasoning. The dose appears in the prescription record anyway; the note's unique contribution is the why. If the rationale isn't written down, it effectively doesn't exist.

5. Omitting the risk statement on "stable" visits. Risk assessment is an every-visit element precisely because stability is an observation, not a guarantee. Two sentences suffice when risk is low; zero sentences never do.

6. Assuming the note is private. It is not a HIPAA psychotherapy note and never can be — 45 CFR § 164.501 excludes medication prescription and monitoring from that category. Write every line knowing that other providers, payers, and potentially the patient will read it.